Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

InflaRx NV IFRX

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.


NDAQ:IFRX - Post by User

<< Previous
Bullboard Posts
Next >>
Post by Sokratesaes86on Jan 09, 2022 10:36am
156 Views
Post# 34297428

Inflarex Countdown to Party

Inflarex Countdown to Party
Inflarex IFRX Germany course 3.80 Biopharma Further decision studies will be completed in the 1st half of 2022 including: Vilobelimab is not a Covid drug !!! It combats sepsis caused by Covid, and sepsis existed before Covid ... and will last long after Covid. Sepsis is one of the most common and cost-intensive diseases in the inpatient area. [1] The World Health Organization (WHO) declared the disease to be one of the leading priorities in the health systems of the member states in 2017 in order to improve the prevention, diagnosis, treatment, recording and follow-up of sepsis patients. Here's a billion dollar market if not so billiards. And Inflarex is on the verge of being the best drug with the fewest side effects. Just a few days!
<< Previous
Bullboard Posts
Next >>